Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Changes in the staging system for HPV+ cancer patients

Hisham Mehanna • 29 Nov 2018
ESMO 2018
General

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, discussing recent changes to the old staging system for HPV-positive cancer patients. Changes to clinical staging and pathological staging are explained.

More from Hisham Mehanna

Improving patient selection for surgical candidates with head and neck cancer
2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna • 30 Sep 2019
The omega score: an emerging biomarker for risk determination
2:12
The omega score: an emerging biomarker for risk determination
Hisham Mehanna • 29 Nov 2018
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna • 29 Nov 2018

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals